Skip to main content
SpringerLink
Log in

Die Hypertonie als ständige Herausforderung unserer Zeit

  • Conference paper
90. Kongreß

Part of the book series: Verhandlungen der Deutschen Gesellschaft für Innere Medizin ((VDGINNERE,volume 90))

  • 29 Accesses

Zusammenfassung

Die 70er Jahre waren im Bereich der Hypertonieforschung durch die vorherrschende Meinung gekennzeichnet, daß zwar hypertonieinduzierte Apoplexie und Nierenversagen, Retinopathie und Kardiomegalie durch Blutdruckkontrolle verhütbar seien, daß aber die sog. atherothrombotischen Komplikationen der Hypertonie, insbesondere Myokardinfarkt und plötzlicher Herztod, trotz intensiver Hochdruckbehandlung nicht vermeidbar sind. Diese Behauptungen stützen sich hauptsächlich auf die Ergebnisse der U.S.P.H.S. Hospitals-Cooperative-Studie (Smith 1977) und der Veterans-Administration-Studien (V.A.).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Freis ED (1979) Treatment of hypertension: State of the Art in 1979. Clin Sci 57: 347s

    Google Scholar 

  2. Helgeland A (1980) Treatment of mild hypertension: A five year controlled drug trial. Am J Med 69: 725–732

    PubMed  CAS  Google Scholar 

  3. Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the HDFP: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2562–2571

    Google Scholar 

  4. Hypertension Detection and Follow-up Program Cooperative Group (1984) Effect of stepped care treatment on the incidence of myocardial infarction and Angina pectoris. 5-Year findings of the hypertension detection and follow-up program. Hypertension [Suppl 1] 6: I-198—I-206

    Google Scholar 

  5. Kornitzer M, DeBacker G, Dramaix M, Kittel F, Thilly C, Graffar M, Vuylsteek K (1983) Belgian heart disease prevention project: Incidence and mortality results. Lancet 1: 1066–1070

    Google Scholar 

  6. Management Committee (1980) The Australian therapeutic trial in mild hypertension. Lancet 1: 1261–1267

    Google Scholar 

  7. Management Committee (1981) Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Med J Aust 2: 398–402

    Google Scholar 

  8. Multiple Risk Factor Intervention Trial Research Group (MRFIT) (1982) JAMA 248: 1465–1477

    Google Scholar 

  9. Prineas RJ, Broste S, Ranataharju R, Crow R, Furberg C, McIntyre K for the MRFIT Research Group (1983) Coronary heart disease six years after risk factor reduction among men with and without ischemic ECG response to exercise. CVD Epidemiology Newsletter, AHA 33: 48

    Google Scholar 

  10. Smith W, McFate (1979) Treatment of mild hypertension: Results of a ten-year intervention trial. U.S. Public Health Service Hospitals Cooperative Study Group. Hypertension XXV. Circ Res [Suppl I] 40: 98–105

    Google Scholar 

  11. Stallones RA (1983) Mortality and the multiple risk factor intervention trial. Am J Epidemiol 117: 647–650

    PubMed  CAS  Google Scholar 

  12. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity and hypertension: Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202: 166

    Google Scholar 

  13. Farsang C, Kapocsi J. Juhasz I, Kunos G (1982) Possible involvement of an endogenous opioid in the antihypertensive effect of clonidine in patients with essential hypertension. Circulation 66: 1268–1272

    PubMed  CAS  Google Scholar 

  14. Ganten D, Hermann K, Bayer C, Unger Th, Lang RE (1983) Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 221: 869–871

    PubMed  CAS  Google Scholar 

  15. Ganten D, Pfaff D (eds) (1983) Central cardiovascular control. In: Current topics in neuroendocrinology, vol 3. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  16. Guyton AC, Coleman TG, Cowley AW, Manning RD, Norman RA, Ferguson JD (1974) A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ Res 35: 159–176

    Google Scholar 

  17. Lundberg JM, Terenius L, Hökfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, Bloom S, Goldstein M (1982) Neuropeptide Y ( NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 116: 477–480

    Google Scholar 

  18. Rettig R, Lang RE, Rascher W, Unger Th, Ganten D (1982) Brain peptides and blood pressure regulation. Clin Sci 63: 269s - 283s

    Google Scholar 

  19. Thoren P, Lundin S (1983) Autonomic nervous system and blood pressure control in normotensive and hypertensive conditions. In: Current topics in neuroendocrinology, vol 3. Springer, Berlin Heidelberg New York Tokyo, pp 31–61

    Google Scholar 

  20. Unger Th, Ganten D, Lang RE (1983) Pharmacology of converting enzyme inhibitors: new aspects. Clin Exp Hypertension A5: 1333–1354

    CAS  Google Scholar 

  21. Blaustein MP (1980) How does sodium cause hypertension? An hypothesis. In: Zumkley H, Losse H (eds) Intracellular electrolytes and arterial hypertension. Thieme, Stuttgart New York, p 151

    Google Scholar 

  22. De Wardener HE, Mac Gregor GA (1980) A possible role of a circulating sodium transport inhibitor in the aetiology of essential hypertension. In: Zumkley H, Losse H (eds) Intracellular electrolytes and arterial hypertension. Thieme, Stuttgart New York, p 86

    Google Scholar 

  23. Losse H, Wehmeyer H, Wessels F (1960) Der Wasser-und Elektrolythaushalt von Erythrozyten bei arterieller Hypertonie. Klin Wochenschr 38: 393–395

    PubMed  CAS  Google Scholar 

  24. Losse H, Zumkley H, Wehmeyer H (1966) Intrazelluläre Elektrolytveränderungen bei arterieller Hypertonie. ( Untersuchungen an Erythrozyten ). Z Kreislaufforsch 55: 113–126

    Google Scholar 

  25. Mac Gregor GA, Smith SJ, Markandu ND, Banks RA (1982) Moderate potassium supplementation in essential hypertension. Lancet 2: 567–570

    Google Scholar 

  26. Overlack A, Stumpe KO, Müller HM, Kolloch R, Krück F (1984) High potassium intake lowers blood pressure in essential hypertension. J Hypertension 2: 114

    Google Scholar 

  27. Skrabal F, Gasser RW, Finkenstedt G, Rhomberg HP, Lochs A (1984) Low-sodium diet versus low-sodium/high-potassium diet for treatment of hypertension. Klin Wochenschr 62: 124–128

    PubMed  CAS  Google Scholar 

  28. Wessels F, Losse H, Zumkley H (1966) Untersuchungen über den Natriumgehalt der Erythrozyten bei Normo-und Hypertonikern mit familiärer Hochdruckbelastung. Verh Dtsch Ges Kreislaufforsch 32: 309–312

    PubMed  CAS  Google Scholar 

  29. Wessels F, Junge-Hülsing G, Losse H (1967) Untersuchungen über die Natriumpermeabilität der Erythrozyten bei Normo-und Hypertonikern mit familiärer Hochdruckbelastung. Z Kreislaufforsch 56: 374–380

    CAS  Google Scholar 

  30. Wessels F, Zumkley H (1980) Sodium metabolism of RBC in hypertensive patients. In: Zumkley H, Losse H (eds) Intracellular electrolytes and arterial hypertension. Thieme, Stuttgart New York, p 59

    Google Scholar 

  31. Zidek W, Lange-Asschenfeld H (1980) Continuous measurements of extracellular ion activities in rat carotid artery by liquid ion exchanger microelectrodes. In: Zumkley H, Losse H (eds) Intracellular electrolytes and arterial hypertension. Thieme, Stuttgart New York, p 19

    Google Scholar 

  32. Zidek W, Losse H, Grünwald J, Zumkley H, Vetter H (1982) Intracellular Na+ and Ca2+ activities in aortic smooth muscle cells from spontaneously hypertensive rats. Res Exp Med 181: 221–224

    CAS  Google Scholar 

  33. Zidek W, Losse H, Dorst KG, Zumkley H, Vetter H (1982) Intracellular sodium and calcium in essential hypertension. Klin Wochenschr 60: 859–862

    PubMed  CAS  Google Scholar 

  34. Zidek W, Kerenyi T, Losse H, Vetter H (1983) Intracellular Na+ and Ca2+ in aortic smooth muscle cells after enzymatic isolation in spontaneously hypertensive rats. Res Exp Med 183: 129–132

    CAS  Google Scholar 

  35. Zumkley H, Losse H (eds) (1980) Intracellular electrolytes and arterial hypertension. Thieme, Stuttgart New York

    Google Scholar 

  36. Bertel O, Bühler FR, Kiowski W, Lütold BE (1980) Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension 2: 130–138

    PubMed  CAS  Google Scholar 

  37. Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JIS, Schalekamp MADH (1977) Mechanisms in hypertension: a personal view. In: Genest J, Koiw E, Kuchel O (eds) Hypertension. Pathophysiology and treatment. McGraw-Hill Book Company, New York St. Louis, pp 529–548

    Google Scholar 

  38. Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH (1977) Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 296: 641–646

    PubMed  CAS  Google Scholar 

  39. Cody RJ, Laragh JH, Case DB, Atlas SA (1983) Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension [Suppl 3] 5: 36–42

    CAS  Google Scholar 

  40. Christensen NJ (1972) Increased levels of plasma noradrenaline in hypothyroidism. J Clin Endocrinol 35: 359–363

    CAS  Google Scholar 

  41. Distler A, Keim HJ, Cordes U, Philipp Th, Wolff HP (1978) Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension. Am J Med 64: 446–451

    PubMed  CAS  Google Scholar 

  42. Distler A (1979) Sympathisches Nervensystem und essentielle Hypertonie. Med Klinik 74: 1735–1741

    CAS  Google Scholar 

  43. Distler A, Kirch W, Lüth B (1980) Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine. Br J Clin Pharmacol 10: 49S - 53S

    PubMed  Google Scholar 

  44. Folkow B, Di Bona G, Hjemdahl P, Torén PH, Wallin BG (1983) Measurement of plasma norepinephrine concentration in human primary Hypertension. A word of caution on their applicability for assessing neurogenic contributions. Hypertension 5: 399–402

    Google Scholar 

  45. Franco-Morselli R, Elghozi JL, Joly E, DiGiulio S, Meyer P (1977) Increased plasma adrenaline concentrations in benign essential hypertension. Br Med J 2: 1251–1254

    PubMed  CAS  Google Scholar 

  46. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN (1978) Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 298: 991–995

    PubMed  CAS  Google Scholar 

  47. Goldstein D (1983) Commentary. Hypertension 5: 402–403

    Google Scholar 

  48. Goldstein DS, Lake CR (1984) Plasma norepinephrine and epinephrine levels in essential hypertension. Fed Proc 43: 57–61

    PubMed  CAS  Google Scholar 

  49. Laragh JH (1983) Personal views on the mechanisms of hypertension. In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension. Physiopathology and treatment. Second edition. McGraw-Hill Book Company, New York St. Louis, pp 615–631

    Google Scholar 

  50. Louis WJ, Doyle AE, Anavekar SN (1975) Plasma noradrenaline concentration and blood pressure in essential hypertension, phaeochromocytoma and depression. Clin Sci Mol Med 48: 239s - 242s

    Google Scholar 

  51. Louis WJ, Doyle AE, Anavekar SN, Johnston CI (1974) Plasma catecholamines, dopamine beta hydroxylase and renin levels in hypertension. In: Distler A, Wolff HP (Hrsg) Hypertension, current problems/Aktuelle Probleme. Thieme, Stuttgart, S 269–276

    Google Scholar 

  52. Man in’t Veld AJ, Schicht IM, Derkx FM, de Bruyn JHB, Schalekamp MADH (1980) Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J 1: 288–290

    Google Scholar 

  53. Philipp Th, Zschiedrich H, Distler A (1979) Einfluß des Angiotensin II-Antagonisten Saralasin auf die Hämodynamik bei Patienten mit renovaskulärer Hypertonie. Klin Wochenschr 55: 917–919

    Google Scholar 

  54. Philipp Th, Distler A, Cordes U (1978) Sympathetic nervous system and blood-pressure control in essential hypertension. Lancet 1: 959–963

    Google Scholar 

  55. Riegger AJG, Lever AF, Millar JA, Morton JJ, Slack B (1977) Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors. Lancet 2: 1317–1319

    PubMed  CAS  Google Scholar 

  56. Ziegler MG, Lake CR (1984) Autonomic degeneration and altered blood pressure control in humans. Fed Proc 43: 62–66

    PubMed  CAS  Google Scholar 

  57. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. N Engl J Med 310: 347–352

    PubMed  CAS  Google Scholar 

  58. Fischer S, Struppler M, Böhlig B, Bernutz C, Wober W, Weber PC (1983) The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. Circulation 68: 821–826

    PubMed  CAS  Google Scholar 

  59. Fischer S, Weber PC (1983) Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5w3). BBRC 116: 1091–1099

    PubMed  CAS  Google Scholar 

  60. Fischer S, Weber PC (1984) Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307: 165–168

    PubMed  CAS  Google Scholar 

  61. Freeman RH, Davis JO, Villarreal D (1984) Role of renal prostaglandins in the control of renin release. Circ Res 54: 1–9

    PubMed  CAS  Google Scholar 

  62. Furchgott RF (1983) Role of endothelium in responses of vascular smooth muscle. Circ Res 53: 558–573

    Google Scholar 

  63. Lorenz R, v Schacky C, Weber M, Meister W, Kotzur J, Reichardt B, Theisen K, Weber PC (1984) Improved aortocoronary by-pass patency by low dose aspirin (100 mg/d) and platelet aggregation and thromboxane formation in graft occlusion. Lancet 1 (in press)

    Google Scholar 

  64. Lorenz R, Spengler U, Fischer S, Duhm J, Weber PC (1982) Platelet function, thromboxane formation and blood pressure contra during supplementation of the western diet with cod liver oil. Circulation 67: 504–511

    Google Scholar 

  65. Margolius HS (1983) Kallikrein and kinins in hypertension. In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension, second edition, pp 360–371

    Google Scholar 

  66. Muirhead EE (1983) The renomedullary antihypertensive system and its putative hormone(s). In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension, second edition, pp 394–407

    Google Scholar 

  67. Neuringer M, Connor WE, van Petten C, Barstad L (1984) Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys. J Clin Invest 73: 272–276

    PubMed  CAS  Google Scholar 

  68. Pedersen EB, Christensen MJ, Christensen P, Johannesen P, Kornerup HJ, Kristensen S, Lauritsen JG, Leyssac PP, Rasmussen A, Wohlert M (1983) Preeclampsia A state of prostaglandin deficiency. Urinary prostaglandin excretion, the renin-aldosterone system, and circulating catecholamines in Preeclampsia. Hypertension 5: 105–111

    Google Scholar 

  69. Scherer B, Witzgall H, Weber PC (1984) Prostaglandin excretion after Furosemide in normal and low-renin essential hypertension. Klin Wochenschr (im Druck )

    Google Scholar 

  70. Siess W, Roth P, Scherer B, Kurzmann I, Böhlig B, Weber PC (1980) Platelet membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet 1: 441–444

    PubMed  CAS  Google Scholar 

  71. v Schacky C, Siess W, Lorenz R, Weber PC (1984) Ungesättigte Fettsäuren, Eicosanoide and Atherosklerose. Internist 25

    Google Scholar 

  72. Weber PC, Siess W, Scherer B, Held E, Witzgall H, Lorenz R (1982) Arachidonic acid metabolities, hypertension and arteriosclerosis. Klin Wochenschr 60: 479–488

    PubMed  CAS  Google Scholar 

  73. Weber PC, Siess W (1982) Interactions of renal prostaglandins with the renin-angiotensin system. Pharmacol Ther 15: 321–337

    Google Scholar 

  74. Weber PC, Scherer B, Held E, Siess W, Stoffel H (1979) Urinary prostaglandins and kallikrein in essential hypertension. Clin Sci 57: 259s - 261s

    PubMed  Google Scholar 

  75. Weber PC, Scherer B (1980) Genetische Disposition als erster Schritt der Hochdruckentstehung. Verh Dtsch Ges Inn Med 86: 285–294

    PubMed  CAS  Google Scholar 

  76. Weber PC, Larsson C, Scherer B (1977) Prostaglandin E2–9-ketoreductase as a mediator of salt intake-related prostaglandin-renin interaction. Nature 266: 65–66

    CAS  Google Scholar 

  77. Weber PC (1983) Vascular resistance and platelet function on cardiovascular drugs and diets affecting prostanoid formation. In: Schettler FG, Gotto AM, Middelhoff G, Habenicht AJR, Jurutka KR (eds) Atherosclerosis VI, pp 715–719

    Google Scholar 

  78. Weber PC, Scherer B, Siess W, Held E (1979) Renale and vaskuläre Prostaglandine. Verh Dtsch Ges Inn Med 85: 1500–1508

    CAS  Google Scholar 

  79. Whorton AR, Young SL, Data JL, Barchowsky A, Kent RS (1982) Mechanism of bradykinin-stimulated prostacyclin synthesis in porcine aortic endothelial cells. Biochim Biophys Acta 712: 79–87

    PubMed  CAS  Google Scholar 

  80. Gross F, Strasser T (1979) Mild hypertension: Natural history and management. Pitman Med. Publ. Co., Kent

    Google Scholar 

  81. Kaplan NM (1978) Clinical hypertension. Williams and Wilkins Co., Baltimore

    Google Scholar 

  82. Swales JD (1979) Clinical hypertension. Chapman and Hall, London

    Google Scholar 

  83. Vetter H, Vetter W (1982) Praktische Hypertonie. Thieme, Stuttgart New York

    Google Scholar 

  84. Maxwell MH (1975) Cooperative study of renovascular hypertension: Current status. Kidney Int 8: 153–160

    Google Scholar 

  85. Vetter H, Siebenschein R, Studer A, Witassek F, Furrer J, Glänzer K, Siegenthaler W, Vetter W (1978) Primary aldosteronism: inability to differentiate unilateral from bilateral adrenal lesions by various routine clinical and laboratory data and by peripheral plasma aldosterone. Acta Endocrinol (Kbh) 89: 710–725.

    CAS  Google Scholar 

  86. Vetter H, Galanski M, Winterberg B, Cramer BM, Fischer M, Zidek W, Greminger P, Tenschert W, Vetter W (1981) Computertomographie bei Nebennierenerkrankungen mit Hormonüberproduktion. Schweiz Med Wochenschr 111: 2051–2054

    PubMed  CAS  Google Scholar 

  87. Sisson JC, Valk TW, Gross MD, Swanson DP, Wieland DW, Tobes MC, Beierwaltes WH (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305: 12–17

    PubMed  CAS  Google Scholar 

  88. Fischer M, Vetter W, Winterberg B, Hengstmann J, Zidek W, Friemann J, Vetter H (1984) Scintigraphic localization of phaeochromocytomas. Clin Endocrinol 14: 1–7

    Google Scholar 

  89. Rahn KH (1982) Frequency and significance of side effects of antihypertensive drugs. Cardiovasc Rev Rep 2: 517–521

    Google Scholar 

  90. Rahn KH (1983) Klinische Pharmakologie neuerer Antihypertensiva. Internist 24: 128–134

    PubMed  CAS  Google Scholar 

  91. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1977) Propranolol in the treatment of essential hypertension. JAMA 237: 2303–2310

    Google Scholar 

  92. Vidt DG, Bravo EL, Fouad FM (1982) Drug therapy: captopril. N Engl J Med 306: 214–219

    PubMed  CAS  Google Scholar 

  93. Groth H, Foerster ECH, Neyses L, Kuhlmann U, Vetter H, Vetter W (1984) Nifedipin beim hypertensiven Notfall und bei schwerer Hypertonie. Schweiz Rundschau Med (Praxis) 73: 45–49

    CAS  Google Scholar 

  94. Havelka J, Vetter H, Studer A, Greminger P, Löscher T, Wollnik S, Siegenthaler W, Vetter W (1982) Acute and chronic effects of the angiotensin converting enzyme inhibitor Captopril in severe hypertension. Am J Cardiol 49: 1467–1474

    PubMed  CAS  Google Scholar 

  95. Spivack C, Ocken S, Frishman WH (1983) Calcium antagonists: Clinical use in the treatment of systemic hypertension. Drugs 25: 154–177

    Google Scholar 

  96. Tenschert W, Vetter W, Studer A, Reuteler H, Furrer J, Nussberger J, Siegenthaler W (1979) Minoxidil bei schwer zu behandelnder Hypertonie. Schweiz Med Wochenschr 109: 1869–1973

    PubMed  CAS  Google Scholar 

  97. Grüntzig A, Kuhlmann U, Vetter W et al. (1978) Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. Lancet 1: 801–802

    PubMed  Google Scholar 

  98. Geyskes CG, Puylaert CBAJ, Oei Hy, Dorhout Mees (1983) Follow up study of 70 patients with renal artery stenosis treated by percutaneous transluminal dilatation. Br Med J 287: 333–336

    CAS  Google Scholar 

  99. Grim CE, Luft FC, Yune Hy et al. (1981) Percutaneous transluminal dilatation in the treatment of renal vascular hypertension. Ann Intern Med 95: 439–442

    PubMed  CAS  Google Scholar 

  100. Sos TA, Pickering TG, Sniderman K et al. (1983) Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N Engl J Med 309: 274–279

    PubMed  CAS  Google Scholar 

  101. Kuhlmann U, Vetter W, Grüntzig A, Schneider E, Pouliadis G, Steurer J, Siegenthaler W (1981) Percutaneous transluminal dilatation of renal artery stenosis: 2 years experience. Science 61: 481s - 483s

    Google Scholar 

  102. Kuhlmann U, Vetter W, Furrer J, Liltolf U, Siegenthaler W, Grüntzig A (1980) Renovascular hypertension: treatment by percutaneous transluminal dilatation. Ann Intern Med 92: 1–6

    PubMed  CAS  Google Scholar 

  103. Foster JH, Maxwell MH, Franklin SS et al. (1975) Renovascular occlusive disease: results of operative treatment. JAMA 231: 1043–1048

    PubMed  CAS  Google Scholar 

  104. Lawrie GM, Morris GC, Soussou ID et al. (1980) Late results of reconstructive surgery for renovascular disease. Ann Surg 191: 528–533

    PubMed  CAS  Google Scholar 

  105. Stanley JC, Fry WJ (1977) Surgical treatment of renovascular hypertension. Arch Surg 112: 1291–1297

    PubMed  CAS  Google Scholar 

  106. Hunt JC, Strong CG (1973) Renovascular hypertension. Mechanism, natural history and treatment. Am J Cardiol 32: 562–574

    Google Scholar 

  107. Case DB, Atlas SA, Marion RM et al. (1982) Long term efficacy of captopril in renovascular and essential hypertension. Am J Cardiol 49: 1440–1445

    PubMed  CAS  Google Scholar 

  108. Havelka J, Vetter H, Studer A et al. (1982) Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol 49: 1467–1474

    PubMed  CAS  Google Scholar 

  109. Vetter W, Welling M, Foerster E-Ch, Boerlin HJ, Greminger P, Vetter H (1984) Long term effect of captopril on kidney function in various forms of hypertension. Klin Wochenschr 62: 731–737

    PubMed  CAS  Google Scholar 

  110. Amery A et al. (1982) Antihypertensive therapy in patients above age 60 years. Eighth Interim Report of the European Working Party on High Blood Pressure in the Elderly. Curr Med Res Opin (Suppl) 8: 1–5

    Google Scholar 

  111. Bock KD (1983) Spezielle Probleme bei der Hochdrucktherapie. Mk Ärztl Fortb 33 /13

    Google Scholar 

  112. Bock KD (1983) Hochdrucktherapie im Alter mit Hydergin: Neue Gesichtspunkte. Schattauer, Stuttgart New York

    Google Scholar 

  113. Bock KD, Anlauf M (1984) Die Qual der Wahl das Dilemma der Hochdrucktherapie. Munch Med Wochenschr 126: 477

    Google Scholar 

  114. Bühler FR, Distler A (1984) Calcium antagonist for antihypertensive baseline therapy. International Symposium, Interlaken, (in press)

    Google Scholar 

  115. Distler A, Phlipp Th (1983) Neuere Entwicklungen in der Hochdrucktherapie. Schattauer, Stuttgart New York

    Google Scholar 

  116. Distler A (1983) Therapie-Indikation bei leichter Hypertonie. Dtsch Med Wochenschr 108: 847–849

    PubMed  CAS  Google Scholar 

  117. Feltkamp H (1984) Behandlung der Hypertonie im Alter erste Ergebnisse der E.W.P.H.E.-Studie. Symposium der Sektion für klinische Geriatrie der Deutschen Gesellschaft für Gerontologie (im Druck)

    Google Scholar 

  118. Gifford RW et al. (1983) The dilemma of “mild” hypertension. JAMA 250: 3171

    PubMed  Google Scholar 

  119. Gross F, Strasser T (eds) (1983) Mild hypertension. Recent advances. Raven Press, New York

    Google Scholar 

  120. Hayduk K, Bock KD (1983) Zengrale Blutdruckregulation durch a2-Rezeptorenstimulation. Steinkopff, Darmstadt

    Google Scholar 

  121. Hayduk K (Hrsg) (1983) Milde Hypertonie. Steinkopff, Darmstadt

    Google Scholar 

  122. Heyden S, Schneider KA (1984) To treat or not to treat mild hypertensives with and without target organ damage (in press)

    Google Scholar 

  123. Holzgreve H (1983) Besonderheiten der Hypertonie im höheren Lebensalter. In: Bock KD (Hrsg) Hochdrucktherapie im Alter mit Hydergin: Neue Gesichtspunkte. Schattauer, Stuttgart New York

    Google Scholar 

  124. Holzgreve H (1983) Beeinflussung der Prognose durch antihypertensive Therapie. In: Distler A, Philipp Th (Hrsg) Neuere Entwicklungen in der Hochdrucktherapie. Schattauer, Stuttgart New York

    Google Scholar 

  125. Laaser U, Amery A, Rasch G, Meurer KA, Kaufmann W (1977) Soll man die Hypertonie im hohen Lebensalter behandeln? Prakt Arzt 7: 1149

    Google Scholar 

  126. Malley O, O’Brien E (1980) Management of hypertension in the elderly. N Engl J Med 302: 1397

    Google Scholar 

  127. Laragh JH (1984) Lessons from antihypertensive drug trials. In: Bühler FR, Distler A (eds) Calcium antagonist for antihypertensive baseline therapy

    Google Scholar 

  128. Murphy B, Dollery C (1983) Calcium antagonists in the treatment of hypertension. Hypertension [Suppl II] 5: 1–129

    Google Scholar 

  129. Stumpe OK, Kolloch R, Overlack A (1983) Neuer Weg in der Hypertoniebehandlung. Herz + Gefäße 3: 446–459

    Google Scholar 

  130. Weidmann P (1983) Langzeitbehandlung der Hypertonie. Schweiz Med Wochenschr 113: 984–1000

    PubMed  CAS  Google Scholar 

  131. Franz I (1982) Ergometrie bei Hochdruckkranken. Springer, Berlin Heidelberg New York

    Google Scholar 

  132. Jahnecke J (1974) Risikofaktor Hypertonie. Boehringer, Mannheim Rost R ( 1979 ) Kreislaufregulation und -adaptation unter körperlicher Belastung. Osang, Bonn

    Google Scholar 

  133. Rost R, Hollmann W (1982) Belastungsuntersuchungen in der Praxis. Thieme, Stuttgart New York

    Google Scholar 

  134. Conen D, Berner U, Dubach UC (1982) Lückenhafte Abklärung und nachlässige Betreuung von ambulanten Patienten mit arterieller Hypertonie. Schweiz Med Wochenschr 112: 1925–1927

    PubMed  CAS  Google Scholar 

  135. Bannan LT, Beevers DG, Jackson SHD (1981) Detecting hypertensive patients. Br Med J 1: 1211–1213

    Google Scholar 

  136. Conen D, Zimmermann W, Berner U (1983) Überzeugende Verbesserung des Hypertonie-Managements durch einfache administrative Maßnahmen. In: Autoreferate zur 51. Jahresversammlung der Schweiz. Gesellschaft für Innere Medizin in Luzern, S 151

    Google Scholar 

  137. L Alderman MH, Charlson ME, Melcher LA (1981) Labelling and absenteeism: The Massachusetts Mutual Experience. Clin Invest Med 4: 165–171

    Google Scholar 

  138. Bärtsch A, Neyses L, Greminger P, Löscher T, Keller U, Bachmann L, Siegenthaler W, Vetter W (1983) Diaprogramm über Hypertonie und Adipositas: eine einfache Methode zur Patienteninformation. Schweiz Med Wochenschr 113: 1929–1933

    PubMed  Google Scholar 

  139. Bannan LT, Beevers DG, Jackson SHD (1981) Detecting hypertensive patients. Br Med J 282: 1211–1213

    CAS  Google Scholar 

  140. Bühler FR, Lèche AS, Schüler G, Gutzwiler F, Baumann F, Schweizer W (1976) Das Hypertonieproblem in der Schweiz, analysiert an Hand einer Blutdruckuntersuchung bei 21 589 Personen. Schweiz Med Wochenschr 106: 99

    PubMed  Google Scholar 

  141. Caldwell JR, Cobb S, Dowling MD, de Jongh D (1970) The drop-out problem in antihypertensive treatment. J Chronic Dis 22: 579–592

    PubMed  CAS  Google Scholar 

  142. Foerster E, Achermann R, Vetter W (1984) Verändert die Blutdruckselbstmessung die Compliance? Verh Dtsch Ges Inn Med (im Druck)

    Google Scholar 

  143. Gatley MS (1968) To be taken as directed. J R Coll Gen Pract 16: 39–44

    PubMed  CAS  Google Scholar 

  144. Haynes RB, Gibson ES, Hackett BC, Sackett DL, Taylor DW, Roberts RS, Johnson AL (1976) Improvement of medication compliance in uncontrolled hypertension. Lancet 2: 1265–1268

    Google Scholar 

  145. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J (1980) Can simple clinical measurement detect patient noncompliance? Hypertension 2: 757–764

    PubMed  CAS  Google Scholar 

  146. Ley P (1972) Comprehension, memory and the success of communicating with the patient. J Inst Health Educ 10: 23–29

    Google Scholar 

  147. Löscher T, Vetter H, Greminger P, Steiner R, Siegenthaler W, Vetter W (1982) Patienten-Compliance. Klin Wochenschr 60: 161–170

    Google Scholar 

  148. Löscher T, Dorst KG, Vetter H, Scheu H, Greminger P, Haase W, Vetter W (1982) Compliancebestimmende Faktoren bei Hypertonikern

    Google Scholar 

  149. Monk M (1981) Blood pressure awareness and psychological well-being in the health and nutrition examination survey. Clin Invest Med 4: 183–189

    PubMed  CAS  Google Scholar 

  150. Moser M, Grellet C, Okin P (1980) Long-term management of hypertension-private practice experience. NY State J Med 80: 1102

    CAS  Google Scholar 

  151. Nessman DG, Carnahan JE, Nugent CA (1980) Increasing compliance. Patient-operated hypertension groups. Arch Intern Med 140: 1427–1430

    Google Scholar 

  152. O’Brian E, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA (1982) Clinic attendance in the hypertension detection and follow-up programm. Hypertension 4: 710–715

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Community and Family Medicine, Duke University, Medical Center, Durham, NC, USA

    S. Heyden

  2. Deutsches Institut zur Bekämpfung des hohen Blutdrucks und Pharmakologisches Institut, Universität Heidelberg, Deutschland

    D. Ganten, Th. Unger, R. E. Lang & H. Vetter

  3. Medizinische Poliklinik der Westfälischen, Wilhelms-Universität Münster, Deutschland

    H. Losse & W. Zidek

  4. Abteilung für allgemeine Innere Medizin und Nephrologie, Universitätsklinikum Steglitz, Berlin, Deutschland

    A. Distler

  5. Medizinische Klinik Innenstadt, Universität München, Deutschland

    P. C. Weber

  6. Poliklinik Bonn, Medizinische Universitäts, Deutschland

    F. Krück

  7. Medizinische Poliklinik, Universität Münster, Deutschland

    H. Vetter

  8. Dept. Innere Medizin, Rijksuniversiteit Limburg, Maastricht, The Nederland

    K. H. Rahn

  9. Departement für Innere Medizin, Universitätsspital Zürich, Schweiz

    W. Vetter & Th. F. Lüscher

  10. Departement für Innere Medizin, Universitätsspital Zürich und Robert-Bosch-Krankenhaus Stuttgart, Schweiz

    P. Greminger & U. Kuhlmann

  11. Medizinische Klinik Köln-Merheim und Poliklinik, Universität Köln, Deutschland

    W. Kaufmann

  12. Institut für Sportmedizin, Universität Dortmund, Deutschland

    R. Rost

  13. Departement für Innere Medizin, Medizinische Universitäts-Poliklinik, Kantonsspital Basel, Schweiz

    U. C. Dubach & D. Conen

Authors
  1. S. Heyden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Ganten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Th. Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. E. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Losse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Zidek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Distler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. C. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Krück
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. H. Rahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. W. Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Greminger
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. U. Kuhlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. W. Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. R. Rost
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. U. C. Dubach
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. D. Conen
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Th. F. Lüscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Heyden, S. et al. (1984). Die Hypertonie als ständige Herausforderung unserer Zeit. In: 90. Kongreß. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 90. J.F. Bergmann-Verlag, Munich. https://doi.org/10.1007/978-3-642-85457-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85457-6_4

  • Publisher Name: J.F. Bergmann-Verlag, Munich

  • Print ISBN: 978-3-8070-0342-9

  • Online ISBN: 978-3-642-85457-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation